Tagged with M

Greece Amgen’s mission is clear cut: ‘To Serve Patients’, which is evident in the level of innovation that they bring as the world’s leading biotech company. Complementary to this message is one that GM of Amgen Greece Arvela Matti, strongly wants to reverberate across the Greek pharmaceutical landscape: innovation is an…

Taiwan Hong-Jen Chang, former Deputy Minister of Health and current CEO and Chairman of the YFY Biotech Management Company, a Taiwan-based VC fund which has been playing an instrumental role in the development of Taiwan’s biotech industry, provides insights into his investment approach and documents the key success factors to prioritize…

Europe Europe accounts for 22.2 percent of global pharma sales; more than Africa, Asia, Australasia, and Latin America combined, but less than half of North America. The biopharmaceutical industry is a key contributor to the European economy in terms of both trade surplus and employment; especially highly-skilled R&D jobs. Germany is…

Greece Equipped with a strong business acumen, Italfarmaco (ITF) Hellas’ Managing Director, Polly Leontaridis-Kalogera emphasizes the critical importance of the decision to focus on women’s health in building a resilient affiliate in the midst of the economic crisis. She shares her insights on the beginnings of the company in Greece, transformative…

Mexico Representatives of Olivares, one of the leading law firms in Mexico, explain the evolving status of cannabis and narcotics for medicinal use in the country. A new Bill authorizing the use of cannabis for medical treatments was passed by the Senate in December 2016, but there is still a long…

Asia 2016 was a year of great activity for the pharma industry, with economic uncertainties, seismic political shifts in the UK and US, and cost-containment measures in several countries. Consequently, PharmaBoardroom surveyed over 400 of its executive readership over four continents to get a sense of their optimism for the industry in 2017.…

Mexico M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican affiliate within the global strategy of the company. Could you introduce yourself to our international readers as well as the…

Greece  Astellas Greece & Cyprus MD, Harry Nardis, emphasizes the importance of integrity, compliance and innovation to the Astellas business model, key priorities, navigating the Greek pharmaceutical landscape while maintaining a high-quality reputation, and retaining the company’s vision of being at the forefront of healthcare change. Having assumed the leadership position…

Taiwan George Lee and Tzu-Ming Pan introduce SunWay Biotech’s groundbreaking red yeast rice extract, ANKASCIN® 568-R, which has been recognized as a New Dietary Ingredient by the US FDA. SunWay Biotech is now bringing this unique product onto the global stage and are considering developing a pharmaceutical product based on the…

Mexico Paulo de Resende, CEO of Laboratorios Grin-Lupin in Mexico, describes the current state of the Mexican pharmaceutical market and explains how the acquisition of Laboratorios Grin will help increase Lupin’s footprint in Latin America by bringing more expertise and R&D resources. Could you please introduce yourself to our international audience…

Switzerland Patient-driven drug pricing, the uncertain future of Switzerland’s tax regime, and new business models for life science innovators in a changing global market are just a few of the topics touched upon by KPMG Switzerland’s head of life sciences Martin Rohrbach. On February 12th the Swiss people rejected the Tax…

Taiwan Tse Wen Chang, internationally recognized as one of the greatest contributors to the biotech field, and founder, CEO, and president of Immunwork, provides insights into the company’s ground-breaking T-E™ pharmaceuticals, which combine both targeting (T) and effector (E) moieties to form a new class of innovative drugs displaying significantly enhanced…